secwatch.observer — SEC 8-K summary
======================================

Issuer:     OSR Holdings, Inc. (OSRH)
CIK:        0001840425
Form:       8-K/A
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0001213900-25-034120
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B
--------------------------------------------------------------------------------

- Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).
- Operating loss increased to ₩15.95B from ₩14.78B; SG&A expenses grew to ₩17.05B.
- Total assets ₩257.6B, equity ₩210.5B; cash and equivalents dropped to ₩502M from ₩697M.
- Key subsidiaries: VAXIMM (Switzerland, biotech), RMC (medical devices, Korea), Darnatein (biotech, Korea).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/0001213900-25-034120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840425/000121390025034120/ea0238120-8ka1_osr.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-034120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer